These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197 [TBL] [Abstract][Full Text] [Related]
5. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer]. Dank M Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175 [TBL] [Abstract][Full Text] [Related]
6. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Goldenberg MM Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534 [TBL] [Abstract][Full Text] [Related]
7. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Shak S Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196 [TBL] [Abstract][Full Text] [Related]
8. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Molina MA; Codony-Servat J; Albanell J; Rojo F; Arribas J; Baselga J Cancer Res; 2001 Jun; 61(12):4744-9. PubMed ID: 11406546 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. Vazquez-Martin A; Colomer R; Brunet J; Menendez JA Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307 [TBL] [Abstract][Full Text] [Related]
10. New insights into anti-HER-2 receptor monoclonal antibody research. Kumar R; Mandal M; Vadlamudi R Semin Oncol; 2000 Dec; 27(6 Suppl 11):84-91; discussion 92-100. PubMed ID: 11236033 [TBL] [Abstract][Full Text] [Related]
11. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. Menendez JA; Vellon L; Lupu R Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499 [TBL] [Abstract][Full Text] [Related]
12. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Hortobagyi GN Semin Oncol; 2001 Dec; 28(6 Suppl 18):43-7. PubMed ID: 11774205 [TBL] [Abstract][Full Text] [Related]
13. [Rationale for Herceptin in the clinical use]. Ebi H; Sasaki Y Nihon Rinsho; 2002 Mar; 60(3):463-7. PubMed ID: 11904959 [TBL] [Abstract][Full Text] [Related]
14. [Herceptin-based therapy for breast cancer]. Tokuda Y; Saito Y; Suzuki Y Nihon Rinsho; 2006 Mar; 64(3):540-5. PubMed ID: 16529047 [TBL] [Abstract][Full Text] [Related]
15. Antibodies as molecular target-based therapy: trastuzumab. Tokuda Y Int J Clin Oncol; 2003 Aug; 8(4):224-9. PubMed ID: 12955577 [TBL] [Abstract][Full Text] [Related]
16. [Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer]. Lehr HA; Schaefer SC; Delaloye JF Rev Med Suisse; 2009 Jul; 5(211):1525-9. PubMed ID: 19694364 [TBL] [Abstract][Full Text] [Related]
17. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448 [TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904 [TBL] [Abstract][Full Text] [Related]
19. [Clinical implications of trastuzumab]. Saeki T; Takashima S Gan To Kagaku Ryoho; 2003 Aug; 30(8):1094-9. PubMed ID: 12938263 [TBL] [Abstract][Full Text] [Related]
20. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]